New Drugs and Therapeutics Update – NGENLA By Dania Al-Hamad, MD, and Christine Yu, MD NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog, was approved…
Read More
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide) Jardiance® (empagliflozin) and Synjardy® (empagliflozin and metformin hydrochlorothiazide)…
Read More
New Meds and Tech from PES Drugs and Therapeutics committee Palovarotene (SohonosTM – Ipsen Pharmaceuticals Inc.) By: Ambika Ashraf, MD and Anna Ryabets-Lienhard, DO Update:…
Read More
Brief Therapeutic Update from PES Drugs and Therapeutics Committee iLet ® Bionic Pancreas On May 19, 2023, the U.S. Food and Drug Administration approved the…
Read More
Brief Therapeutic Update from PES Drugs and Therapeutics Committee Sogroya® (somapactian) Once weekly Sogroya® (somapacitan-beco, Novo Nordisk) was approved by the United States Food and Drug…
Read More
Brief Therapeutic Update from PES Drugs and Therapeutics Committee The MiniMed™780G System The MiniMed 780G System from Medtronic was approved by the US Food and Drug…
Read More
Dexcom G7 In December 2022, the Dexcom G7 continuous glucose monitor system was cleared by the FDA for use in people age 2 and older…
Read More
Wegovy® (semaglutide) once weekly injection is a glucagon-like peptide 1 receptor agonist (GLP1-RA) approved by the FDA in June, 2021 for weight management in adults. Wegovy…
Read More
Difficulty filling prescriptions for diazoxide have been reported intermittently. Teva Pharmaceuticals reports that Proglycem® Oral Suspension 50 mg/mL 30 mL (NDC 00575-6200-30) is currently available. Providers…
Read More
On November 17, 2022, the FDA announced the approval of TZIELDTM (teplizumab-mzwv), which is a CD-3 directed monoclonal antibody. This first-in-class therapy is intended to delay…
Read More